COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off our Print & eBook bundle option. Terms & conditions.
Hyaluronan Signaling and Turnover - 1st Edition - ISBN: 9780128000922, 9780128003930

Hyaluronan Signaling and Turnover, Volume 123

1st Edition

0.0 star rating Write a review
Authors: Melanie Simpson Paraskevi Heldin
Hardcover ISBN: 9780128000922
eBook ISBN: 9780128003930
Imprint: Academic Press
Published Date: 23rd July 2014
Page Count: 418
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Preface
  • Chapter One: Emerging Roles for Hyaluronidase in Cancer Metastasis and Therapy
    • Abstract
    • 1 Introduction
    • 2 Of Mole Rats and Men: Insights About HA and Cancer
    • 3 Hyaluronidase Expression in Cancer
    • 4 Hyaluronidase Function and the Metastatic Process
    • 5 Hyaluronidase Targeting in Cancer Therapy and Imaging
    • 6 Conclusions and Future Perspective
    • Acknowledgments
  • Chapter Two: Targeting Hyaluronic Acid Family for Cancer Chemoprevention and Therapy
    • Abstract
    • 1 Introduction
    • 2 Targeting HA Production
    • 3 Targeting HA Signaling
    • 4 HA as a Carrier for Drug Delivery
    • 5 Targeting HA Receptors
    • 6 Targeting HAase
    • 7 Conclusion
    • Acknowledgments
  • Chapter Three: Aberrant Posttranscriptional Processing of Hyaluronan Synthase 1 in Malignant Transformation and Tumor Progression
    • Abstract
    • 1 Splicing and Cancer
    • 2 Control of Pre-mRNA Splicing
    • 3 Impact on Cancer of Alterations in Splicing Machinery
    • 4 Aberrant Splicing of Hyaluronan Synthase 1
    • 5 Clinical Impact of Aberrant HAS1 Splicing
    • 6 Genetic Variations in HAS1
    • 7 Functional Impact of HAS1Vs
    • 8 Functional Outcomes of HAS1Vs in Transfectants
    • 9 HAS1Vs and Mitotic Catastrophe
    • 10 Conclusion
    • Acknowledgments
  • Chapter Four: Hyaluronan Synthases Posttranslational Regulation in Cancer
    • Abstract
    • 1 Introduction
    • 2 HA Synthesis
    • 3 HA Catabolism
    • 4 HAS2 Phosphorylation, AMPK, and Its Dual Effects on Tumors
    • 5 O-GlcNAcylation and Cancer
    • 6 Conclusions
    • Acknowledgment
  • Chapter Five: Hyaluronan-Coated Extracellular Vesicles—A Novel Link Between Hyaluronan and Cancer
    • Abstract
    • 1 Introduction
    • 2 Extracellular Vesicles as Novel Communicators Between Cells
    • 3 EVs Promote Tumor Progression
    • 4 HA Synthesis Enhances Shedding of Extracellular Vesicles
    • 5 HA–EVs as Predictors, Targets, and Carriers of Therapy
    • 6 Conclusions
    • Acknowledgments
  • Chapter Six: Hyaluronan in the Healthy and Malignant Hematopoietic Microenvironment
    • Abstract
    • 1 Introduction
    • 2 BM MSC, Their Derivatives, and HA
    • 3 Macrophages and HA in the BM
    • 4 Endothelial Cells and HA in BM
    • 5 Nerve Cells and HA in BM
    • 6 Role of HA in the BM Microenvironment in Hematological Malignancies
    • 7 Conclusion
  • Chapter Seven: Hyaluronan Regulation of Endothelial Barrier Function in Cancer
    • Abstract
    • 1 Introduction
    • 2 HA Regulation of Vascular Integrity
    • 3 HA Regulation of Endothelial Barrier Function During Tumor Angiogenesis
    • 4 HA Regulation of Endothelial Barrier Function During Cancer Metastasis
    • 5 Potential Therapeutic Effects of HMW-HA in Inhibiting Endothelial Barrier Disruption During Cancer Progression
    • 6 Conclusions
    • Acknowledgments
  • Chapter Eight: HAS2 and CD44 in Breast Tumorigenesis
    • Abstract
    • 1 Introduction
    • 2 Molecular Classification of Breast Cancer
    • 3 Role of Stromal HA in Tumor Progression
    • 4 Expression of HAS Genes and Breast Cancer Malignancy
    • 5 HA–CD44 Interactions: A Regulatory Network During TGFβ-Mediated EMT
    • 6 Conclusions
    • Acknowledgments
  • Chapter Nine: CD44 is a Multidomain Signaling Platform that Integrates Extracellular Matrix Cues with Growth Factor and Cytokine Signals
    • Abstract
    • 1 Introduction
    • 2 Ligation of ECM Components by CD44
    • 3 CD44: Coreceptor for Cell-Surface Receptors
    • 4 CD44 as a Multidomain Signal Integration Platform
    • 5 Concluding Remarks
  • Chapter Ten: Hyaluronan–CD44 Interaction Promotes Oncogenic Signaling, microRNA Functions, Chemoresistance, and Radiation Resistance in Cancer Stem Cells Leading to Tumor Progression
    • Abstract
    • 1 Introduction
    • 2 Regulation of Tumor Progression by HA/CD44
    • 3 Activation of CSCs by HA/CD44
    • 4 Conclusion
    • Acknowledgments
  • Chapter Eleven: Advances and Advantages of Nanomedicine in the Pharmacological Targeting of Hyaluronan-CD44 Interactions and Signaling in Cancer
    • Abstract
    • 1 Introduction
    • 2 Importance of Targeting Hyaluronan–CD44 in Tumors
    • 3 Therapeutic Interventions/Strategies That Target Hyaluronan and/or CD44 to Perturb Hyaluronan-CD44 Interactions in Tumors
    • 4 Advances in Nanomedicine Related with Hyaluronan-CD44 Targeting
    • 5 Concluding Remarks/Conclusions
    • Acknowledgments
  • Chapter Twelve: Hyaluronan/RHAMM Interactions in Mesenchymal Tumor Pathogenesis: Role of Growth Factors
    • Abstract
    • 1 Introduction
    • 2 The Role of Hyaluronan and Its Receptors in Fibrosarcoma
    • 3 GF Signaling and ECM Organization in Fibrosarcoma Pathogenesis
    • 4 Concluding Remarks
  • Chapter Thirteen: CD147: Regulator of Hyaluronan Signaling in Invasiveness and Chemoresistance
    • Abstract
    • 1 Introduction
    • 2 Structure and Pleiotropic Functions of CD147
    • 3 CD147-Induced HA Synthesis and Signaling
    • 4 CD147–HA Axis in Cellular Invasion
    • 5 CD147–HA Axis in Chemoresistance
    • 6 Induction of the CD147–HA Axis by Kaposi's Sarcoma-Associated Herpesvirus
    • 7 Conclusions
  • Index


Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers hyaluronan signaling and turnover.

Key Features

  • Provides information on cancer research
  • Outstanding and original reviews
  • Suitable for researchers and students


Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


No. of pages:
© Academic Press 2014
23rd July 2014
Academic Press
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Authors

Melanie Simpson

Affiliations and Expertise

Department of Biochemistry, University of Nebraska, USA

Paraskevi Heldin

Paraskevi Heldin

Paraskevi Heldin, Ph.D., received her B.Sci. exam (Chemistry/Biochemistry Mathematics), Uppsala University in 1979 and her Ph.D., in Medical and Physiological Chemistry for studies on regulatory phosphorylation of proteins, Faculty of Medicine, Uppsala University, in 1987. After dissertation she changed research area and focused on the biology of hyaluronan under the supervision of Professor T.C. Laurent, Uppsala University. She worked at Department of Medical and Physiological Chemistry during 1987- 2000, and was awarded Docent appointment in Medical and Physiological Chemistry and Scientist Position from The Göran Gustafsson Foundation. Since 2001, she is Adjunct Associate Professor at the Department of Medical Biochemistry and Microbiology, and Associate Investigator and Head of the Matrix Biology Group in Ludwig Institute for Cancer Research, Uppsala, Sweden. Year 2013, she has appointed Adjunct Professor at the Department of Medical Biochemistry and Microbiology, Uppsala Unversity, Sweden. Dr Heldin’s interests are focused on understanding the mechanisms of how hyaluronan-CD44 complexes interact with the receptors for the growth factors PDGF and TGFβ for modulation of the proliferative and invasive behavior of malignant cells.

Affiliations and Expertise

Ludwig Institute for Cancer Research Ltd, Sweden